In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $621.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salveen Richter’s rating is based on Vertex Pharmaceuticals’ promising product launches and pipeline developments. The company has introduced Alyftrek for cystic fibrosis, which is expected to see significant uptake among patients, particularly those who were previously ineligible for CFTR modulators. This is anticipated to result in a majority of Trikafta patients transitioning to Alyftrek, indicating strong market potential.
Additionally, the launch of Journavx for acute pain is progressing well, with notable reimbursement advancements and inclusion in hospital formularies. The company’s pipeline also shows promise with developments in chronic pain treatment, potential accelerated approval for povetacicept in IgAN, and upcoming data for zimislecel in type 1 diabetes. These factors collectively support a positive outlook for Vertex Pharmaceuticals, justifying the Buy rating.
In another report released on June 9, Bank of America Securities also maintained a Buy rating on the stock with a $567.00 price target.
VRTX’s price has also changed slightly for the past six months – from $469.220 to $451.520, which is a -3.77% drop .